Compare Stocks: IMNM, KRYS, KYMR, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$71.86 +4.5%	$82.82	$31.45 ▼ $95.49	$9.69B	1.28	1.93 million shs	2.67 million shs
IMNM Immunome	$25.75 +2.7%	$25.44	$9.85 ▼ $30.06	$2.85B	2.13	1.04 million shs	1.06 million shs
KRYS Krystal Biotech	$350.88 +5.1%	$343.68	$158.08 ▼ $382.54	$9.88B	0.54	260,384 shs	274,525 shs
KYMR Kymera Therapeutics	$122.06 +3.7%	$114.70	$50.35 ▼ $130.05	$9.78B	1.96	677,679 shs	779,356 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.47%	-14.73%	-21.03%	-13.90%	+124.14%
IMNM Immunome	+4.59%	+2.12%	-12.10%	+29.69%	+166.99%
KRYS Krystal Biotech	-0.84%	-1.82%	-3.67%	-1.87%	+104.10%
KYMR Kymera Therapeutics	-0.07%	+2.65%	-1.78%	+19.77%	+139.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$71.86 +4.5%	$82.82	$31.45 ▼ $95.49	$9.69B	1.28	1.93 million shs	2.67 million shs
IMNM Immunome	$25.75 +2.7%	$25.44	$9.85 ▼ $30.06	$2.85B	2.13	1.04 million shs	1.06 million shs
KRYS Krystal Biotech	$350.88 +5.1%	$343.68	$158.08 ▼ $382.54	$9.88B	0.54	260,384 shs	274,525 shs
KYMR Kymera Therapeutics	$122.06 +3.7%	$114.70	$50.35 ▼ $130.05	$9.78B	1.96	677,679 shs	779,356 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.47%	-14.73%	-21.03%	-13.90%	+124.14%
IMNM Immunome	+4.59%	+2.12%	-12.10%	+29.69%	+166.99%
KRYS Krystal Biotech	-0.84%	-1.82%	-3.67%	-1.87%	+104.10%
KYMR Kymera Therapeutics	-0.07%	+2.65%	-1.78%	+19.77%	+139.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.64	Moderate Buy	$99.15	37.98% Upside
IMNM Immunome	2.85	Moderate Buy	$35.18	36.63% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.80	4.25% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$133.21	9.13% Upside

Current Analyst Ratings Breakdown

Latest IMNM, KRYS, KYMR, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$132.00 ➝ $152.00
9/21/2026	IMNM Immunome	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
9/21/2026	KRYS Krystal Biotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$392.00 ➝ $400.00
9/14/2026	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$123.00 ➝ $144.00
9/10/2026	KYMR Kymera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$180.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/8/2026	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$108.00
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	12.20	$0.13 per share	556.78	$3.64 per share	19.74
IMNM Immunome	$6.94M	421.42	N/A	N/A	$5.75 per share	4.48
KRYS Krystal Biotech	$389.13M	26.69	$7.60 per share	46.19	$42.06 per share	8.34
KYMR Kymera Therapeutics	$39.21M	258.84	N/A	N/A	$19.42 per share	6.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	43.97	37.61	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)

Latest IMNM, KRYS, KYMR, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
IMNM Immunome	N/A	15.08	15.08
KRYS Krystal Biotech	N/A	8.32	7.96
KYMR Kymera Therapeutics	N/A	10.34	10.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IMNM Immunome	44.58%
KRYS Krystal Biotech	86.29%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
IMNM Immunome	7.21%
KRYS Krystal Biotech	13.10%
KYMR Kymera Therapeutics	15.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable

IMNM, KRYS, KYMR, and ARWR Headlines

Recent News About These Companies

Stifel Nicolaus Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock

September 22 at 8:05 AM | marketbeat.com

Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR

September 22 at 3:04 AM | marketbeat.com

Kymera Therapeutics stock gains as biotech sector strength follows recent earnings

September 18, 2026 | ad-hoc-news.deA

J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

September 18, 2026 | theglobeandmail.com

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Intuitive Surgical (ISRG)

September 15, 2026 | theglobeandmail.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 15, 2026 | americanbankingnews.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages

September 15, 2026 | marketbeat.com

BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

September 14, 2026 | marketscreener.comM

Kymera Therapeutics, Inc. $KYMR Shares Sold by California State Teachers Retirement System

September 14, 2026 | marketbeat.com

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 11, 2026 | seekingalpha.com

Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR

September 10, 2026 | marketbeat.com

Brian Adams Sells 6,371 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

September 5, 2026 | insidertrades.com

36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc

September 5, 2026 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock

September 4, 2026 | marketbeat.com

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

September 4, 2026 | zacks.com

Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR

September 4, 2026 | marketbeat.com

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

September 3, 2026 | zacks.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR

September 3, 2026 | marketbeat.com

Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR

September 3, 2026 | marketbeat.com

21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, KRYS, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$71.86 +3.07 (+4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$71.36 -0.50 (-0.69%)

As of 07:44 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Immunome NASDAQ:IMNM

$25.75 +0.68 (+2.71%)

Closing price 04:00 PM Eastern

Extended Trading

$25.87 +0.12 (+0.47%)

As of 07:30 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Krystal Biotech NASDAQ:KRYS

$350.88 +17.03 (+5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$359.58 +8.69 (+2.48%)

As of 07:58 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Kymera Therapeutics NASDAQ:KYMR

$122.06 +4.39 (+3.73%)

Closing price 04:00 PM Eastern

Extended Trading

$121.98 -0.08 (-0.06%)

As of 07:30 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, KRYS, KYMR, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, KRYS, KYMR, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, KRYS, KYMR, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, KRYS, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Immunome NASDAQ:IMNM

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMNM, KRYS, KYMR, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMNM, KRYS, KYMR, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMNM, KRYS, KYMR, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM, KRYS, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Immunome NASDAQ:IMNM

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools